NEW YORK, July 5, 2016 /PRNewswire/ --
The Biotech arena continues to compete with pricing pressures and economic uncertainty, but the overall performance of each operator varies on spending growth and demand. In today's pre-market research, Stock-Callers.com directs investors' attention to four stocks in this industry to review their recent performances: XOMA Corp. (NASDAQ: XOMA), Navidea Biopharmaceuticals Inc. (NYSE: NAVB), Radius Health Inc. (NASDAQ: RDUS), and Cara Therapeutics Inc. (NASDAQ: CARA). Learn more about these stocks and receive your complimentary trade alerts at:
To access Stock-Callers.com full PDF Research Packages for free, please visit the links below.
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
XOMA Research Package: http://stock-callers.com/registration/?symbol=XOMA
NAVB Research Package: http://stock-callers.com/registration/?symbol=NAVB
RDUS Research Package: http://stock-callers.com/registration/?symbol=RDUS
CARA Research Package: http://stock-callers.com/registration/?symbol=CARA
Last Friday, Berkeley, California headquartered XOMA Corp.'s stock climbed 4.45% to close the day at $0.57. A total volume of 1.17 million shares was traded, which was higher than their three months average volume of 1.12 million shares. The Company's shares are trading 16.40% below their 50-day moving average. Additionally, shares of XOMA Corp., a development stage biotechnology Company, discovers, develops, and commercializes antibody-based therapeutics in the U.S., Europe, and the Asia Pacific, have a Relative Strength Index (RSI) of 46.07.
Shares in Dublin, Ohio headquartered biopharmaceutical Company, Navidea Biopharmaceuticals Inc. gained 1.42%, finishing Friday's session at $0.54. The stock recorded a trading volume of 562,892 shares. The Company's shares are trading below their 50-day moving average by 41.65%. Furthermore, shares of Navidea Biopharmaceuticals, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 23.58.
Cambridge, Massachusetts headquartered biopharmaceutical Company, Radius Health Inc.'s stock finished 4.84% higher at $38.53 last Friday at the close and with a total volume of 635,458 shares traded. The Company's shares have advanced 16.65% in the previous three months. The stock is trading above its 50-day moving average by 9.00%. Additionally, shares of Radius Health, which focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the U.S., have an RSI of 58.91.
Shares in Shelton, Connecticut headquartered clinical-stage biopharmaceutical Company, Cara Therapeutics Inc. ended last Friday's session 6.24% higher at $5.11. The stock recorded a trading volume of 505,629 shares. The Company's shares are trading 10.82% below their 50-day moving average. Moreover, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the U.S., have an RSI of 45.99.
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA